NewAmsterdam Pharma Company N.V. (NAMS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 2:40 PM EDT
Company Participants
Michael Davidson – CEO, President & Executive Director
Conference Call Participants
Asad Haider – Goldman Sachs Group, Inc., Research Division
Presentation
Asad Haider
Goldman Sachs Group, Inc., Research Division
NewAmsterdam, very pleased to have — Michael, welcome — can I give you the opportunity to maybe just level set us and make some opening framing remarks on the company.
Michael Davidson
CEO, President & Executive Director
Sure. Thanks. Thanks, everyone, for being here. We’ve had a really productive year firing on all cylinders. I mean our — all our trials are rolling along on schedule or ahead of schedule. Of course, the most important being PREVAIL, which is our 9,500 patient outcome study, and I think we announced just a few months ago that we’re going to do an interim analysis based on a number of factors, we can go into more detail, but that interim-analysis — we’ll start the actual point at the end of this year, the readout will be in the first quarter of next year.
Question-and-Answer Session
Asad Haider
Goldman Sachs Group, Inc., Research Division
Well, that’s, I guess, one of the most — that’s a great segue into what I think is probably going to take a lot of the discussion, the PREVAIL trial, given how important it is. I want to just maybe double-click a little bit more on the interim analysis. I think just first is on timing. You said it’s going to be done by the end of the year with the results in the first quarter…
Michael Davidson
CEO, President & Executive Director
Well, you said event rate time point, which is going to be the end of this year approximately. And then
